Nucala (mepolizumab)

pCPA File Number: 20946

Negotiation Status:

Concluded with an LOI

Indication(s):

Severe Eosinophilic Asthma

Sponsor/Manufacturer:

GlaxoSmithKline Inc.

CDA-AMC Project Number:

SR0461-000

pCPA Engagement Letter Issued:

2016-10-21

Negotiation Process Concluded:

2017-11-24